Introduction
Apoptosis is an essential physiological process that plays a critical role in development, tissue homeostasis, and defense against pathogens (Adams, 2003; Cuconati and White, 2002; Danial and Korsmeyer, 2004) . The dying cell undergoes several biochemical and morphological changes and is eventually engulfed by neighboring cells. Bcl-2 family members are either proapoptotic or antiapoptotic and are key regulators of apoptotic signaling through mitochondria. The mitochondrial intermembrane space is a storehouse of proapoptotic proteins that are released from mitochondria during apoptosis enabling activation of some caspases. Caspases, a family of cysteine proteases that are activated by cleavage, are the executioners of apoptosis that implement apoptosis by selective cleavage of cellular substrates that implement the orderly dismantling of the cell.
Apoptosis can be triggered by a variety of physiological and pathological stimuli such as cytokines, hormones, viruses, and toxic insults, among many others. Tumor necrosis factor-a (TNF-a) is representative of a family of trimeric cytokines such as Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL) (Nagata, 1999) . Many cell types produce TNF-a, including macrophages, monocytes, lymphocytes, keratinocytes, and fibroblasts, in response to inflammation, infection, injury, and other environmental challenges (Baud and Karin, 2001) . A broad spectrum of responses is elicited by TNF-a, including activation and migration of lymphocytes and leukocytes, cell proliferation, differentiation, survival, and apoptosis. Activation of apoptosis by TNF-a in vitro requires coordinate inhibition of survival signaling by addition of protein synthesis inhibitors (Perez and White, 2000) that inhibit the generation of prosurvival factors mediated by NF-kB (Kucharczak et al., 2003) . Engagement of TNF-a with tumor necrosis factor-a receptor 1 (TNFR1) results in the recruitment of adaptor proteins that facilitate multimerization, autocatalytic cleavage, and activation of caspase-8 in a death-inducing signaling complex (DISC) (Igney and Krammer, 2002) . In certain cell types, mitochondria amplify death signaling by enabling activation of caspase-9, which then activates other downstream caspases. Although several steps in the activation and regulation of TNF-a-mediated death signaling have been determined, our understanding of the signaling pathway is far from complete.
We report here that amino-terminally truncated versions of deleted in breast cancer-1 (DBC-1) are generated during TNF-a-mediated cell death. DBC-1 is one of the genes cloned from human chromosome region 8p21 (Hamaguchi et al., 2002) , a region homozygously deleted in breast cancers. Endogenous 150 kDa DBC-1 underwent caspase-dependent processing during TNF-a-mediated death signaling to generate p120 DBC-1 and p66 DBC-1, both of which included the carboxy-terminus of the protein. DBC-1 was nuclear in healthy cells, however during apoptosis, DBC-1 localized to the cytoplasm. Overexpression of amino-terminal truncations of DBC-1, resembling p120 DBC-1 and carrying the carboxy-terminal coiled-coil region, caused mitochondrial clustering and mitochondrial matrix condensation, and sensitized cells to TNF-a-mediated apoptosis. Thus, the truncated forms of DBC-1, by playing a role in sensitizing cells to apoptosis, could function in tumor suppression. DBC-1, like its relative cell cycle and apoptosis regulatory protein-1 (CARP-1) (Rishi et al., 2003) , may thus, also participate in the regulation of apoptosis. DBC-1 may be another example of caspase-dependent generation of a proapoptotic protein product during apoptosis that facilitates the orderly process of cell death.
Results

Predicted domain structure of DBC-1 and related proteins
During partial purification of protein complexes with a potential involvement in apoptosis , we identified a 120 kDa protein that was specifically generated in cells treated with TNF-a plus cycloheximide (TNF/CHX) that was not observed in untreated cells. Mass spectrometry analysis of p120 yielded six peptides that matched Homo sapiens DBC-1 in the database (Figure 1a) .
DBC-1 is located on human chromosome region 8p21, within the region 8p21-23 that is homozygously deleted in breast and some other cancers (Hamaguchi et al., 2002) . DBC-1 is predicted to encode a 923 aminoacid protein, and PROSITE and BLAST protein homology searches yielded a domain map of DBC-1 shown in Figure 1b . The protein is predicted to have a nuclear localization signal (NLS) and a leucine zipper at the amino-terminus, and an EF hand (calmodulin-like calcium-binding region) and a coiled-coil domain at its carboxy-terminus. DBC-1 has orthologs in Rattus norvegicus (Accession number XP_224329) and Mus musculus (accession number AAH21475) (Figure 1c ).
DBC-1 shows significant homology to CARP-1 (Figure 1c, d ) (Accession number AAO17319) (Rishi et al., 2003) , a protein coded for by an open reading frame in human chromosome 10q22.1. However, DBC-1 lacks the SAF-A/B, acinus, and PIAS domain (SAP domain) of CARP-1 (Figure 1b , c, and d). SAP domains are predicted DNA-binding domains involved in chromosomal organization, transcription, DNA repair, apoptotic chromatin remodeling, and degradation, and the DNA-condensing activity of SAP-domain containing proteins is activated by caspase cleavage during apoptosis (Aravind and Koonin, 2000) . CARP-1 is proapoptotic (Rishi et al., 2003) and has orthologs in Caenorhabditis elegans (Accession number NP_502696), Anopheles gambiae (accession number XP_310631), and Arabidopsis thaliana (Accession number NP_178414) (Figure 1d ). Thus, plants and invertebrates have orthologs of CARP-1, while mammals encode both DBC-1 and CARP-1.
DBC-1 is processed in a caspase-dependent manner into p120 DBC-1 in vivo during apoptosis
To investigate the function of DBC-1 and the origin of the novel p120 polypeptide specifically generated in TNF/CHX-treated cells, we produced an antiserum to a region in the carboxy-terminus of human DBC-1. The antibody recognized 150 kDa authentic endogenous DBC-1 by Western blotting in whole-cell lysates from healthy HeLa cells (Figure 2a ). The other substantially fainter bands were also present in Western blots probed with the pre immune sera indicating that they were nonspecific. We will refer to this p150 DBC-1 as DBC-1 henceforth. To examine DBC-1 during TNF-a-mediated death signaling, HeLa cells were treated with TNF-a alone, CHX alone, or TNF/CHX for 0, 4, 8, 16 h and whole-cell extracts were resolved by SDS-PAGE and Western blotted for DBC-1. In HeLa cells, TNF/CHX induces caspase-8 activation, cytochrome c and SMAC release from mitochondria, caspase-9 and -3 activation, chromatin condensation, and apoptotic cell death (White et al., 1992; Perez and White, 2000; ). The DBC-1 antiserum recognized endogenous full-length DBC-1, but also p120 DBC-1 and p66 DBC-1 that were specifically generated during TNF/CHX treatment, and not during treatment with TNF-a or CHX alone (Figure 2a) . Concomitant with the appearance of p120 DBC-1 and p66 DBC-1 in TNF/CHX-treated cells, the levels of DBC-1 decreased (Figure 2a) , consistent with proteolytic processing of DBC-1 into p120 DBC-1 and p66 DBC-1. p120 DBC-1 was detected at 4 h, an early point in TNF-a-mediated apoptosis (Figure 2a ), suggesting that it might participate in the death process rather than being a consequence of cell death. Caspase-8 processing served as a marker for TNF-a-mediated apoptosis, and the amount of full-length protein decreased with time (Figure 2a) , indicative of activation (Perez and White, 2000) .
To determine if the generation of p120 DBC-1 and p66 DBC-1 were specific to TNF-a-mediated apoptosis or were a common feature of many apoptotic signaling pathways, HeLa cells were treated with staurosporine (STS) or etoposide (ET) that induce apoptosis through activation of caspase-9 and -3 but not caspase-8. Following STS or ET treatment for 0, 3, 6, and 24 h, DBC-1 was examined to determine if p120 DBC-1 and p66 DBC-1 were generated in response to other death signals. p120 DBC-1 and p66 DBC-1 were also generated in cells undergoing STS-and ET-mediated apoptosis (Figure 2a) . Thus, the generation of p120 Caspase-dependent processing of DBC-1 and apoptosis R Sundararajan et al DBC-1 and p66 DBC-1 may be a common feature of many apoptotic pathways induced by diverse stimuli. DBC-1 was examined in the presence of a caspase inhibitor z-VAD-FMK to determine if p120 DBC-1 was generated from DBC-1 by caspase-dependent processing during TNF-a-mediated apoptosis. HeLa cells undergoing TNF-a-mediated apoptosis were treated with or without z-VAD-FMK during TNF/CHX treatment. As controls, healthy cells were also treated with or without z-VAD-FMK. p120 DBC-1 was generated in the TNF/ CHX-treated samples, while z-VAD-FMK prevented the generation of p120 DBC-1 during TNF-a-mediated death signaling (Figure 2b ). Thus, inhibition of caspase activity prevented the generation of p120 DBC-1, indicating that endogenous DBC-1 was processed in a caspase-dependent manner into p120 DBC-1 during TNF-a-mediated apoptosis. This observation is also consistent with the coordinate reduction in DBC-1 and induction of p120 DBC-1 during apoptosis (Figure 2a) .
To determine if p120 DBC-1 and p66 DBC-1 represented the amino-terminus or carboxy-terminus of DBC-1, HeLa cells transiently overexpressing DBC-1 V5 (carboxy-terminally tagged DBC-1) were untreated or treated with TNF/CHX for 4 h. Cell lysates were resolved by SDS-PAGE and Western blotted with V5 antibody. The V5 antibody recognized DBC-1 V5 , but also recognized p120 DBC-1 V5 and p66 DBC-1 V5 ( Figure 2c ). This indicated that p120 DBC-1 and p66 DBC-1 that were generated by activation of apoptosis encompassed the carboxy-terminus of DBC-1. Moreover, mass spectrometry analysis of p120 yielded no peptides near the amino-terminus of DBC-1 with the most aminoterminal peptide encompassing amino acids 281-309, which resides carboxy-terminal to the NLS (Figure 1a ). Taken together, this suggests that caspasedependent processing of DBC-1 removes the aminoterminus to generate p120 DBC-1 and p66 DBC-1.
Endogenous DBC-1 localizes to the nucleus in healthy cells and to the cytoplasm during apoptosis HeLa cells were examined by indirect immunofluorescence using DBC-1 antiserum to study the localization of endogenous DBC-1, and to examine whether there is any change in localization upon generation of p120 DBC-1 during TNF-a-mediated death signaling. In healthy cells, DBC-1 localized mainly in the nucleus, as seen by bright nuclear staining and confirmed with Hoescht dye staining, with faint cytoplasmic staining ( Figure 3, top panel) . In the TNF/CHX-treated samples, DBC-1 localized in the nucleus in flat cells, however, once the death process was initiated as evidenced by changes in cell morphology, DBC-1 localized to the cytoplasm and appeared largely excluded from the Whole-cell extracts were prepared, resolved on 7.5% SDS-PAGE and processed for Western blotting with DBC-1 antiserum. (c) Both p120 DBC-1 and p66 DBC-1 include the carboxy-terminus of DBC-1. HeLa cells were transfected with pCDNA3.1 (control vector) or 6 mg of pCDNA3.1/V5-His-DBC-1, untreated or treated with TNF/CHX for 4 h, whole-cell extracts prepared, and processed for Western blotting with anti-V5 antibody nucleus (Figure 3, bottom panel) . This is consistent with the caspase-dependent generation of p120 DBC-1 during TNF-a-mediated death signaling, which is predicted to remove the amino-terminus of the protein, possibly including the NLS (Figure 1b ).
Overexpressed DBC-1 localizes to nuclei and mitochondria and causes clustering of mitochondria To determine if there was any function associated with DBC-1, the full-length protein was overexpressed in HeLa cells. Vector control and DBC-1 tagged at the amino-terminus (DBC-1 Xpress ) were transiently expressed in HeLa cells for 24 h, untreated or treated with TNF/ CHX for 4 h, and indirect immunofluorescence was performed using the Xpress antibody to detect DBC-1 Xpress . Cells were also stained with Mitotracker CMXRos to detect mitochondria in order to address the subcellular localization of overexpressed DBC-1 with respect to mitochondria. Cells transfected with the vector control plasmid were negative for Xpress antibody staining and displayed normal mitochondrial distribution ( Figure 4a) ; however, in the presence of TNF/CHX, approximately 10% of the flat cells showed mitochondria clustering around the nucleus (Figure 4b ). Cells eventually lost mitochondrial membrane potential as they died with classic apoptotic morphology as indicated by Hoechst dye staining and electron microscopy (data not shown). In healthy cells, overexpressed DBC-1 localized to the nucleus (Figure 4c) , as did the endogenous protein ( Figure 3 , top panel). However, about a third of the cells showed the presence of cytoplasmic clusters of DBC-1 in addition to nuclear localization. Many of the cytoplasmic clusters of DBC-1, overlapped with mitochondria, and in these cells mitochondrial distribution was altered and mitochondria were also clustered ( Figure 4d ). Following 4 h of TNF/CHX treatment, overexpressed DBC-1 was still mostly nuclear, however, almost all the cytoplasmic clusters of DBC-1 now colocalized with clustered mitochondria (Figure 4e ). Similar results were obtained when DBC-1 was transiently expressed for 48 h (data not shown).
Perinuclear clustering of mitochondria in cells undergoing TNF-a-mediated apoptosis has been observed, and has been attributed to defective kinesin transport of the organelle (De Vos et al., 1998 . Thus, we examined mitochondria in healthy cells and in cells undergoing TNF-a-mediated apoptosis by indirect immunofluorescence using an antibody to p110, a mitochondrial marker protein. The mitochondria in healthy cells displayed normal mitochondrial pattern (well-spread in the cell and 'worm-like' pattern) ( Figure 4f , top panel). However, following 4 h of TNF/CHX treatment, 65% of the cells exhibited punctiform mitochondria dispersed throughout the cell, while the remaining 35% of the cells (flat cells and cells undergoing change in morphology induced by the death process) displayed mitochondria that have disappeared from the cell periphery to form clusters around the 
DBC-1 overexpression does not induce or inhibit apoptosis
Since p120 DBC-1 was generated during apoptosis and overexpressing DBC-1 was associated with clustered mitochondria, we determined if overexpressed DBC-1 induced or inhibited apoptosis. Hence, DBC-1 V5 was transiently expressed in HeLa cells for 24 or 48 h along with a marker plasmid pDsRed2-C1 to monitor viability and transfection efficiency, both in the presence and absence of TNF/CHX. The number of flat red cells compared to the total cell number remained almost the same in both the vector-expressing or DBC-1 V5 -expressing samples both in the untreated and 4 h treated TNF/ CHX samples ( Figure 5 ). In this same assay, overexpression of proapoptotic Bax induces profound apoptosis, and overexpression of antiapoptotic E1B 19 K (adenovirus Bcl-2 homolog) protects from cell death (Han et al., 1996) . This indicated that transiently expressing DBC-1 in HeLa cells did not kill cells nor did it protect cells from TNF-a killing. We were, however, unable to generate HeLa cells that stably overexpress DBC-1, suggesting that elevated long-term expression may be detrimental. Caspase-dependent processing of DBC-1 and apoptosis R Sundararajan et al Deletion of the amino-terminus of DBC-1 results in cytoplasmic localization p120 DBC-1 and p66 DBC-1 encompass the carboxyterminus of DBC-1 and carry the coiled-coil region. Interestingly, mitofusins Mfn1 and Mfn2 that coordinately regulate mitochondrial fusion, morphology and distribution (Santel and Fuller, 2000; Legros et al., 2002; Chen et al., 2003) , also possess a coiled-coil region at their carboxy-termini that is required for mitochondrial targeting . We generated a mutant of DBC-1 that resembled p120 DBC-1 (Figure 6a , DN264 DBC-1) to test whether p120 DBC-1 was targeted to mitochondria and had any function. Endogenous p120 DBC-1 has approximately 30 kDa of its amino-terminus removed and may have lost the NLS (Figure 1a, b) . There are many aspartic acids in DBC-1 that follow the NLS that represent potential caspase cleavage sites ( Figure 1a ). Hence, a specific caspase cleavage site to potentially mutate and inactivate was not apparent, and it is still not clear if p120 DBC-1 is a direct caspase cleavage product. DN264 DBC-1, a mutant of DBC-1 that is missing 264 amino acids at the amino-terminus including the predicted NLS and leucine zipper, should closely approximate p120 DBC-1.
DN264 DBC-1 tagged at the amino-terminus (DN264 DBC-1 Xpress ) was transiently expressed in HeLa cells for 24 h to determine its intracellular localization. The transfected cells were either untreated or treated with TNF/CHX for 4 h hours and examined by indirect immunofluorescence using the Xpress antibody to detect DN264 DBC-1
Xpress and Mitotracker CMXRos to detect mitochondria.
The loss of the amino-terminus of the protein including the NLS in DN264 DBC-1 Xpress resulted in the protein being exclusively cytoplasmic. Diffuse cytoplasmic localization (Figure 6b Furthermore, the complete loss of nuclear localization of the mutant protein (as compared to the wild-type DBC-1 protein) indicated that p120 DBC-1 generated during TNF-a-mediated death signaling might have a similar localization.
To determine if the carboxy-terminal coiled-coil region conferred mitochondrial localization, morphology, or distribution as has been reported for other proteins, another mutant that contained only the extreme carboxy-terminus of DBC-1 including the coiled-coil region (Figure 6a , DN703 DBC-1) was generated. DN703 DBC-1 tagged at the amino-terminus (DN703 DBC-1 Xpress ) was transiently expressed in HeLa cells to determine its intracellular localization. At 24 h, cells were untreated or treated with TNF/CHX for 4 h and examined by indirect immunofluorescence using the Xpress antibody to detect DN703 DBC-1 Xpress and Mitotracker CMXRos to detect mitochondria. Figure 6b , top panel), while in the remaining cells, it localized in cytoplasmic aggregates or in distinct foci that overlapped exactly with MitoTracker Red CMXRos staining as seen in the confocal microscopy images (Figure 6c) . Expression of DN703 DBC-1
Xpress caused the mitochondria to cluster or fuse into these multiple foci (Figure 6c ). In cells treated with TNF/CHX, the percentage of cells overexpressing DN703 DBC-1
Xpress dramatically decreased and the remaining cells, which were not yet dead, showed the presence of these mitochondrial foci (data not shown). Similar results were obtained when the protein was transiently expressed in HeLa cells for 48 h (data not shown). This suggested that DN703 DBC-1 Xpress may be sensitizing cells to killing by TNF/CHX (see below).
To determine if the coiled-coil region was the sole determinant of cytoplasmic localization of DBC-1, DC220 DBC-1 and DC130 DBC-1 were generated (Figure 6a , DC220 DBC-1 and DC130 DBC-1). Cells overexpressing DC220 DBC-1
Xpress and DC130 DBC-1 Xpress ( Figure 6a ) showed exclusive nuclear localization (data not shown). This indicated that the coiled-coil region of DBC-1 was responsible for the formation of the cytoplasmic clusters seen in Figure 4d 
Expression of amino-terminally deleted DBC-1 sensitizes cells to TNF-a-mediated apoptosis
The reduction in DN264 DBC-1 Xpress and DN703 DBC-1 Xpress positive cells upon TNF/CHX treatment suggested that expression of amino-terminally truncated DBC-1 might promote apoptosis. To test this, wild-type DBC-1, DN264 DBC-1, and DN703 DBC-1 tagged at the amino-terminus (DBC-1 Xpress and DN703 DBC-1 Xpress dramatically decreased upon TNF/CHX treatment both at 24 and 48 h post-transfection, in contrast to wild-type DBC-1 Xpress expression (Figure 7) . Thus, DN264 DBC-1 Xpress and DN703 DBC-1 Xpress sensitized cells to TNF-amediated apoptosis, while wild-type DBC-1 did not induce or inhibit apoptosis. There were more positive DBC-1 mutant-transfected cells compared to wild-type DBC-1 (Figure 7) . To address whether mutant proteins were expressed at higher levels than wild-type, which could account for the death promoting activity, we examined levels of expression of wild-type and mutant proteins by Western blotting. The expression levels of DBC-1 Xpress , DN264 DBC-1 Xpress , and DN703 DBC-1 Xpress were equivalent (data not shown) indicating that the sensitivity of detection was higher for the mutant proteins.
Taken together, p120 DBC-1 and p66 DBC-1 that contained the carboxy-terminal coiled-coil region, and that were generated in a caspase-dependent manner during TNF-a-mediated death signaling, might function similarly to the amino-terminal truncation mutants of DBC-1 and sensitize cells to TNF-a-mediated apoptosis. Since p120 DBC-1 and p66 DBC1 were generated as early as at 4 h of TNF-a-mediated death signaling, they could cause clustering and perhaps fusion of mitochondria and feed-forward the process of death.
Amino-terminal truncations of DBC-1 induce mitochondrial condensation and clustering
The ultrastructure of mitochondria in cells undergoing apoptosis have been characterized and mitochondria are seen to change morphology from an 'orthodox' state to a 'condensed' state (Hackenbrock, 1966; Mancini et al., 1997; Zhuang et al., 1998; Martinou et al., 1999; Desagher and Martinou, 2000; Scorrano et al., 2002; Gottlieb et al., 2003) . Since overexpressed wild-type and particularly amino-terminally truncated mutants of DBC-1 caused mitochondrial clustering, we investigated the ultrastructure of these mitochondria to understand the mechanism of action of the mutant proteins that resembled p120 DBC-1 and contained the carboxyterminal coiled-coil region. HeLa cells expressing DN264 DBC-1
Xpress and DN703 DBC-1 Xpress were examined by electron microscopy 24 h post-transfection. were clustered around the nucleus and many of their mitochondria were in the 'condensed' state, that is, the mitochondrial matrix had condensed and well-defined cristae were absent (Figure 8b, c, e, f) . The matrices in many mitochondria appear as discontinuous fragments of membrane-bounded matrix. However, these 'fragments' may represent cross-sections of branches that are continuous with the main matrical mass in another plane (Hackenbrock, 1966) . Cells transiently expressing DN264 DBC-1
Xpress and DN703 DBC-1 Xpress showed no release of cytochrome c from mitochondria (data not shown). Thus, p120 DBC-1 and p66 DBC-1 generated during TNF-a-mediated death signaling could cause mitochondrial clustering and mitochondrial matrix condensation, which could mobilize cytochrome c for release from mitochondria and sensitize cells to TNF-amediated apoptosis.
Discussion
Human chromosome region 8p21-8p23 is frequently deleted in various cancers, including breast cancer, and the genes residing therein are being interrogated as potential tumor suppressors (Fujiwara et al., 1994; Sunwoo et al., 1996; He et al., 1997; Baffa et al., 2000; Dai et al., 2000; Dong, 2001; Kurimoto et al., 2001; Lassus et al., 2001; Martinez-Climent et al., 2001; Knosel et al., 2002; Swalwell et al., 2002; Thor et al., 2002; Kahng et al., 2003; Lai et al., 2003; Plaumann et al., 2003; Xu et al., 2003) . 8p21 is homozygously deleted in breast cancers and genes in this deleted region include DBC-1, Deleted in Breast Cancer-2 (DBC-2), TNFRSF10A, TNFRSF10B, EGR3, and KIAA0273 (Hamaguchi et al., 2002) . Examination of the mRNA expression pattern of DBC-1 in a variety of neoplastic and normal cells and tissues shows that the DBC-1 transcript is lost in 16% (3/19) of neoplastic breast cell lines, 14% (2/14) of neoplastic lung cell lines, 8% (1/12) of neoplastic colon cell lines, and 0% (0/11) of other neoplastic cell lines. In contrast, 100% of normal breast (8/8), lung (1/1), placenta (2/2), and brain tissues (3/3) have DBC-1 mRNA expression and it appears otherwise ubiquitously expressed (Hamaguchi et al., 2002) . However, the screening of 60 cancer cell lines shows no codon-altering point mutations of DBC-1 (Hamaguchi et al., 2002) . Thus, the functional role of DBC-1 in normal cells and the role of loss of DBC-1 in cancer are not entirely clear, and evidence suggests a possible role for nearby DBC-2 in tumor suppression (Hamaguchi et al., 2002) .
DBC-1 possesses an NLS and primarily localizes in the nucleus in healthy cells. Wild-type DBC-1 is not proapoptotic or antiapoptotic, and presumably functions in the nucleus in a manner unrelated to apoptosis. However, during apoptosis, caspase activity generates carboxy-terminal proapoptotic forms of DBC-1 (p120 DBC-1 and p66 DBC-1) that facilitate the death process. Thus, DBC-1 may be a member of a class of proapoptotic proteins, the activity of which is revealed upon caspase activation and processing. p120 DBC-1 was detected at an early point in TNF-a-mediated apoptosis, suggesting that it might participate in the death process rather than being a consequence of cell death. Caspase cleavage products of many cellular substrates have been shown to be proapoptotic and expedite the death process, while cleavage of other proteins helps in the disassembly of the apoptotic cells (Kothakota et al., 1997; Chiu et al., 2002; Kim et al., 2002; Fischer et al., 2003; Nachmias et al., 2003) . Alternatively, some caspase substrates are cleaved so as to inactivate their antiapoptotic function (Cryns and Yuan, 1998) .
DBC-1 shows significant homology to CARP-1, a perinuclear, B130 kDa protein coded for by an open reading frame in human chromosome 10q22.1 (Rishi et al., 2003) . CARP-1 upregulates p21
, downregulates expression of cell cycle regulatory proteins, including c-Myc and cyclin B1, and induces apoptosis when overexpressed. CARP-1 is an SAP domain containing protein and this class of proteins has members whose proapoptotic activity is activated upon cleavage by caspases and that promote nuclear condensation associated with apoptotic cell death (Gohring et al., 1997; Sahara et al., 1999; Zamzami and Kroemer, 1999; Kipp et al., 2000) . However, whether CARP-1 is cleaved by caspases during apoptosis has not yet been determined.
Processing of DBC-1 in a caspase-dependent manner to generate p120 DBC-1 and p66 DBC-1 during TNF-amediated death signaling causes cytoplasmic localization. p120 DBC-1, generated during TNF-a-mediated apoptosis in a caspase-dependent fashion, may be a caspase cleavage product of DBC-1. There are an abundance of aspartic acids that may function as potential cleavage sites (around 30 to 35 on DBC-1, some of which immediately follow the NLS). It will be of interest to determine if p120 DBC-1 is indeed generated by direct caspase cleavage or if it is generated indirectly by caspase activity. Nevertheless, caspase inhibitor studies show that the generation of p120 DBC-1 is caspase-dependent.
Amino-terminally truncated DBC-1, which resembles p120 DBC-1, localizes exclusively to the cytoplasm when overexpressed, and promotes mitochondrial clustering and mitochondrial matrix condensation, and sensitizes cells to apoptosis. In cells overexpressing the aminoterminally truncated DBC-1, vimentin and tubulin distribution remains unaffected, indicating that DBC-1 acts independently of the cytoskeleton to cause perinuclear clustering of mitochondria (data not shown). Mitochondrial clustering (De Vos et al., 1998 Thomas et al., 2000) and mitochondrial matrix condensation (Hackenbrock, 1966; Mancini et al., 1997; Zhuang et al., 1998; Martinou et al., 1999; Desagher and Martinou, 2000; Scorrano et al., 2002; Gottlieb et al., 2003) are central features of several apoptotic pathways. The carboxy-terminal coiled-coil region of DBC-1 is necessary and sufficient for the mitochondrial clustering and mitochondrial matrix condensation, at least when overexpressed. Coiled-coil regions are involved in protein-protein interactions and are involved in localization to and clustering of mitochondria. They mediate intermitochondrial adhesion/docking, probably by formation of four-helix bundle as seen in SNARE proteins . Overexpressed mitofusins, which also contain a carboxy-terminal coiled-coil region, and mediate mitochondrial fusion, induce perinuclear clustering of mitochondria (Santel and Fuller, 2000; Legros et al., 2002; Rojo et al., 2002) . Furthermore, aminoterminally truncated DBC-1 sensitizes cells to TNF-amediated apoptosis. Mitochondrial fission and fusion has been implicated in apoptosis, and proteins that alter mitochondrial physiology and morphology are involved in apoptosis (Karbowski and Youle, 2003) . Evidence suggests that the mitochondrial matrix condensation and unraveling of cristae mobilizes cytochrome c for release, which facilitates cytochrome c release upon insertion of a BH3-containing protein in the mitochondrial membrane (Gottlieb et al., 2003) . Loss of mitochondrial membrane potential, inhibition of ATPases, and lack of substrates for oxidative phosphorylation all cause mitochondrial condensation (Hackenbrock, 1968; Gottlieb et al., 2003) . Thus, the aminoterminal truncations of DBC-1 could through their coiled-coil region be targeted to the mitochondria and cause matrix condensation directly or indirectly. Alternatively, amino-terminally truncated DBC-1 may be antagonized by a prosurvival function of DBC-1, an activity that is eventually lost due to proteolytic cleavage.
It would be valuable to determine if loss of DBC-1 functions to promote the occurrence of breast and others cancers. Since DBC-1 processing during apoptosis sensitizes cells to die, deletion of DBC-1 or mutations that render DBC-1 resistant to processing may impair apoptosis, thereby promoting tumor growth. Thus, caspase-dependent processing and activation of proapoptotic activity of DBC-1 may function in tumor suppression. To determine whether knocking down DBC-1 will reduce the apoptotic function of TNF-a, we attempted to downregulate DBC-1 by using siRNA targeted against DBC-1. However, since DBC-1 appears to be a very stable protein, we were unable to knock down DBC-1 levels (data not shown). Moreover, if restoration of DBC-1 to null cells restores apoptotic function remains to be explored.
Materials and methods
Mass spectrometry analysis
HeLa cells were untreated or treated for 4 h with TNF-a and a protein synthesis inhibitor cycloheximide (TNF/CHX) (2000 U/ml of TNF-a (Boehringer Mannheim, Indianapolis, IN, USA) and 30 mg/ml of CHX (Sigma, St. Louis, MO, USA) to block the NF-kB-activated survival pathway as previously described (White et al., 1992; Perez and White, 2000; . p120 was identified in partially fractionated extracts of TNF/CHX-treated, but not untreated, HeLa cells. To determine the identity of p120, it was gel isolated, and protein sequence analysis was performed at the Harvard Microchemistry Facility (Cambridge, MA, USA) by microcapillary reverse-phase HPLC nano-electrospray tandem mass spectrometry (mLC/MS/MS) on a Finnigan LCQ DECA quadrupole ion trap mass spectrometer. Apart from the nonspecific contaminants keratin and bovine serum albumin, the sequence of six peptides was obtained, all of which were present in Homo sapiens DBC-1.
Isolation of HeLa RNA and reverse transcription (RT) reaction
RNA was isolated from HeLa cells using the RNeasy mini protocol for isolation of total RNA from animal cells (Qiagen, Valencia, CA, USA). The RT reaction was carried out using the SuperScriptt First-Strand Synthesis system for RT-PCR (Invitrogen, Carlsbad, CA, USA) using oligo dT primers.
Plasmids
PCR was carried out on the first-strand cDNA synthesized by RT-PCR with DBC-1 gene-specific primers using the Advantaget-HF 2 PCR DNA kit (BD Biosciences Clontech, Palo Alto, CA, USA). The PCR product was excised from the gel, gel purified using the QIAEX II agarose gel extraction protocol (Qiagen), and was cloned into the two mammalian expression vectors pCDNA4/HisMax-TOPO and pCDNA3.1/ V5-His-TOPO according to the manufacturer's instructions (Invitrogen). The primers used to generate pCDNA4/HisMax-DBC-1 were as follows (forward primer: 5 0 -ATGTCC CAGTTTAAGCGCCAGCGGATCAACCCG-3 0 and reverse primer: 5 0 -TCAGTTGCTAGGTGCCGGCTCCTCCTTCTC CAC-3 0 ). The primers used to generate pCDNA3.1/V5-His-DBC-1 were as follows (forward primer: 5 0 -ATGTCCCA GTTTAAGCGCCAGCGGATCAACCCG-3 0 and reverse primer: 5 0 -GTTGCTAGGTGCCGGCTCCTCCTTCTCCAC CCA-3 0 ). A PCR product generated using the following primers (forward primer: 5 0 -TCAGCCTTCCCCCTGAGC CAGCCCTTTTCC-3 0 and reverse primer: 5 0 -TCAGTTGC TAGGTGCCGGCTCCTCCTTCTCCAC-3 0 ) and encoding DN264 DBC-1 (amino acid 265-923) was subcloned into mammalian expression vector pCDNA4/HisMax-TOPO vector (Invitrogen) to generate pCDNA4/HisMax-TOPO-DN264 DBC-1. A PCR product generated using the following primers (forward primer: 5 0 -GACTGTCTGCTTGCTTTTGTGTTCT TTGATGCC-3 0 and reverse primer: 5 0 -TCAGTTGCTAGGT GCCGGCTCCTCCTTCTCCAC-3 0 ) and encoding DN703 DBC-1 (amino acid 704-923) was subcloned into mammalian expression vector pCDNA4/HisMax-TOPO vector (Invitrogen) to generate pCDNA4/HisMax-TOPO-DN703 DBC-1. A PCR product generated using the following primers (forward primer: 5 0 -ATGTCCCAGTTTAAGCGCCAGCGGATCAA CCCG-3 0 and reverse primer: 5 0 -TCATAAGGGGAGCA CAGCAGAGGGATCCAG-3 0 ) and encoding DC220 DBC-1 (amino acid 1-703) was subcloned into mammalian expression vector pCDNA4/HisMax-TOPO vector (Invitrogen) to generate pCDNA4/HisMax-TOPO-DC220 DBC-1. A PCR product generated using the following primers (forward primer: 5 0 -ATGTCCCAGTTTAAGCGCCAGCGGATCAACCCG-3 0 and reverse primer: 5 0 -TCAACCTGGCTTCGTGCTTTT CCCAGGAGG-3 0 ) and encoding DC130 DBC-1 (amino acid 1-793) was subcloned into mammalian expression vector pCDNA4/HisMax-TOPO vector (Invitrogen) to generate pCDNA4/HisMax-TOPO-DC130 DBC-1. A PCR product generated using the following primers (forward primer: 5 0 -AAGGATGAGGCACAGAATGAGGGCCCGGCTACA-3 0 and reverse primer: 5 0 -TCAGGCTGAGAACCGGTTATGG CTCTCCTCCAG-3 0 ) that encodes a part of DBC-1 protein (amino acid 599-849) was subcloned into pCR T7/NT-TOPO vector (Invitrogen) for recombinant protein expression and purification. Sequences of all plasmids generated were confirmed by automated DNA sequencing (UMDNJ Robert Wood Johnson Medical School DNA Synthesis and Sequencing Core Facility, Piscataway, NJ, USA). The pDsRed2-C1 plasmid (BD Biosciences Clontech) was used as a marker for determining transfection efficiency.
Antibodies
The following antibodies were used: rabbit polyclonal anticaspase-8 antibody (BD Biosciences Pharmingen, San Diego, CA, USA); mouse monoclonal anti-Xpress antibody (Invitrogen); mouse monoclonal anti-V5 antibody (Invitrogen); and mouse monoclonal anti-human p110 mitochondrial protein antibody (Oncogene Research Products, San Diego, CA, USA). The DBC-1 rabbit polyclonal antiserum was generated as follows: pCR T7/NT-TOPO-DBC-1 (amino acids 599-849 of human DBC-1 described above) was transformed into Escherichia coli BL21; recombinant histidine-tagged fusion protein production was induced with IPTG; and protein purification was carried out using the QIAexpressionist system (Qiagen Inc.) according to the manufacturer's instructions using a denaturing purification scheme. Purified, recombinant DBC-1 (amino acids 599-849) was then gel isolated, and used for immunization in rabbits to generate polyclonal antiserum (Cocalico Biologicals, Inc., Reamstown, PA, USA). The anti-DBC-1 antiserum was highly specific and recognized the antigen, transiently overexpressed DBC-1 and endogenous p150 DBC-1 in HeLa and other cell lines, whereas preimmune serum showed no reactivity.
Transfection
HeLa cells were electroporated with 6 mg of pCDNA3.1/Zeo (control vector), 6 mg of pCDNA4/HisMax-DBC-1, 6 mg of pCDNA4/HisMax-DN264 DBC-1, or 6 mg of pCDNA4/ HisMax-DN703 DBC-1 for the indicated indirect immunofluorescence experiments. The experiments were carried out 24 h post-transfection unless otherwise mentioned.
TNF-a and inhibitor studies
HeLa cells were untreated or treated for 4 h (unless otherwise indicated) with TNF/CHX as previously described (White et al., 1992; Perez and White, 2000; . Treatment of cells with CHX alone has no effect on caspase activation, Bax conformation, or cell viability (White et al., 1992; Perez and White, 2000; . HeLa cells were also treated with TNF-a alone or CHX alone for 0, 4, 8, 16 h. Where indicated, HeLa cells were pretreated with 10 mM z-Val-Ala-Asp-fluoromethyl ketone (z-VAD-FMK) (Sigma) for 1 h before and during TNF/CHX treatment. HeLa cells were treated with 4 mM staurosporine (Sigma) for 0, 3, 6, 24 h or treated with 100 mM etoposide (Sigma) for 0, 3, 6, 24 h.
Indirect immunofluorescence
Cells were fixed in PBS containing 3.7% paraformaldehyde and permeabilized with PBS containing 0.5% Triton X-100 (Sigma). Cells were incubated with the indicated antibodies and visualized with goat anti-mouse fluorescein-conjugated secondary antibody, goat anti-mouse rhodamine-conjugated secondary antibody (for anti-p110 primary antibody), or goat anti-rabbit rhodamine-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Fixed cells on coverslips were incubated with 0.5 mg/ml Hoechst dye (Molecular Probes, Eugene, OR, USA) for 10 min at room temperature and washed three times with PBS, prior to mounting. Mitochondria were stained using Mitotracker Red CMXRos (Molecular Probes) according to the manufacturer's instructions. Photography was performed using a microscope equipped with epifluorescence optics (model FXA; Nikon Inc., Garden City, NY, USA). Confocal images were captured as a single optical section with frame averaging using a Leica TCS SP2 confocal system with a Leica DM-IRE2 inverted microscope (Leica Microsystems Inc., Bannockburn, IL, USA).
Viability assays
Hela cells were transfected with 6 mg of pcDNA3.1 (control vector) or 6 mg of pCDNA3.1/V5-His-DBC-1 to express DBC-1, and 2 mg pDsRed2-C1 to express Red Fluorescent Protein as a marker for transfection efficiency. At 24 and 48 h posttransfection, cells were untreated or treated with TNF/CHX (as described above). The number of flat red fluorescing cells and total number of cells in at least three different fields were counted for each condition. The average percentage of flat (healthy) red cells was calculated for each condition and graphed along with standard deviations. In another type of viability assay, HeLa cells were electroporated with 6 mg of pCDNA4/HisMax-DBC-1, 6 mg of pCDNA4/HisMax-DN264 DBC-1 or 6 mg of pCDNA4/HisMax-DN703 DBC-1. At 24 and 48 h post-transfection, cells were untreated or treated with TNF/CHX (as described above). The percentage of cells expressing DBC-1 Xpress , DN264 DBC-1 Xpress , and DN703 DBC-1 Xpress was determined in each condition by counting immunolabeled cells expressing the Xpress-tagged protein in a given field of cells. The counting was repeated in three different fields and in two independent experiments. The average percent positive cells was calculated in each case and graphed along with standard deviations.
Electron microscopy
HeLa cells were electroporated with 6 mg of pCDNA3.1/Zeo (control vector), 6 mg of pCDNA4/HisMax-DN264 DBC-1, or 6 mg of pCDNA4/HisMax-DN703 DBC-1. At 24 h posttransfection, cells were harvested using trypsin/EDTA and were fixed in EM fixative (2.5% gluteraldehyde þ 4% paraformaldehyde in 0.1 M cacodylate buffer). Cells were then postfixed in 1% Osmium Tetroxide, dehydrated in a graded series of acetone (50, 70, 90, and 100%) and embedded in epon/spurr resin. Sections (90 nm) were cut and placed on a copper grid. The grid was stained with uranyl acetate and lead citrate. The samples were examined using a JEOL 1200EX electron microscope.
